Tristel Plc (AIM: TSTL) has quietly strung together another year of double-digit growth, yet the infection-prevention specialist rarely features in mainstream market commentary. On 22 July 2026 the company said unaudited Revenue for the year to 30 June 2026 rose 10% to £51.1m, with adjusted pre-tax profit up at least 14% to no less than £11.5m, cash of £16.0m and no debt. A new chief executive, Chris Lee, took the helm on 1 August, days after the group launched 3T Pro, its first paid digital product.

With a Market Capitalisation of around £192m and shares at roughly 400p on 2 September 2026, according to lse.co.uk, the question is whether a consistent, cash-generative AIM company with a growing United States footprint is still being overlooked, or whether the market has already priced in its ambitions.

Trading update: FY26 revenue up 10% and profit ahead of consensus

The most important recent announcement is the positive trading update of 22 July 2026 for the financial year ended 30 June 2026. Revenue increased 10% to £51.1m from £46.5m in FY25, while adjusted profit before tax is expected to be no less than £11.5m, a 14% improvement on £10.1m. The adjusted EBITDA Margin remained above the 25% target and the Balance Sheet was debt-free, with cash of £16.0m at 30 June 2026 against £12.8m a year earlier.

Tristel (LSE:TSTL) said the outcome matched market consensus for revenue of £51.1m and was slightly ahead of consensus adjusted pre-tax profit of £11.4m. Anna Wasyl, chief financial officer and then interim chief executive, said: "We are delighted to deliver another year of significant growth with strong Demand for our infection prevention products globally." The group continued "to meet our performance targets of delivering double-digit revenue growth each year, and maintaining adjusted EBITDA margins of at least 25%," she added.

Two further developments frame the update. On 17 June 2026 Tristel (LSE:TSTL) appointed Christopher Lee as chief executive from 1 August 2026, replacing Matt Sassone, who left on 30 June for a worldwide president role at a large US multinational. Lee previously ran Summit Medical and Venner Medical International and spent 18 years at Johnson & Johnson; chairman Bruno Holthof said his "industry experience, especially in the US, makes him the ideal person to lead the business." On 27 July 2026 the group launched 3T Pro, a premium paid tier of its 3T digital compliance platform offering enhanced asset tracking, dashboards and audit reporting. No pricing or revenue guidance was disclosed.

What Tristel does

Tristel manufactures infection-prevention products based on proprietary chlorine dioxide chemistry, sold to hospitals in more than 40 countries through 19 subsidiaries and distributors. According to the FY25 results published on 13 October 2025, the Tristel Brand of high-level disinfectants for medical devices generated 87% of sales, the Cache brand of sporicidal surface disinfectants 8%, and other income, including royalties, 5%. It describes itself as the only provider of chlorine dioxide-based high-level disinfectants both validated and regulated for semi-critical devices.

Overseas sales accounted for 63% of FY25 revenue, with the United Kingdom at 37%. Germany and Western Europe are the largest overseas contributors, followed by Australia and Asia Pacific. The United States remains small but is the strategic priority: Tristel ULT, a foam for ultrasound probes, is sold through partner Parker Laboratories, and Tristel OPH for ophthalmic devices received FDA 510(k) clearance in May 2025. The group employs roughly 267 people.

Half-year numbers: revenue up 14%, US sales multiply

The most detailed recent figures are the interim results for the six months to 31 December 2025, published on 2 March 2026. Revenue rose 14% to £25.65m, with UK sales up 13% to £9.88m and overseas sales up 14% to £15.77m. Adjusted EBITDA increased 17% to £7.34m, a 29% margin, adjusted pre-tax profit rose 11% to £5.47m and reported pre-tax profit climbed 36% to £4.96m. Basic Earnings Per Share were 8.28p, up 45%, and adjusted EPS was 9.36p against 8.17p. Gross margin was 81%.

Medical device decontamination contributed 88% of first-half revenue and grew 15%, while surface disinfection grew 30% to £2.3m. US revenue jumped 542% to £262k, helped by clinical validation at the Mayo Clinic and Johns Hopkins and updated AIUM guidelines recognising chlorine dioxide foam. The Interim Dividend was held at 5.68p, and cash and investments stood at £13.29m after £4.07m of dividend payments.

FY25 (year to 30 June 2025) delivered reported pre-tax profit of £8.4m, basic EPS of 13.92p, a full-year dividend of 14.20p, up 5%, and Operating Cash Flow of £10.3m.

What could drive the shares next

The first catalyst is the audited FY26 results, scheduled for October 2026, followed by the AGM in December. Investors will look for detail behind the £11.5m adjusted profit floor and any fresh commentary from Chris Lee in his first outing as chief executive.

The US remains the growth story. Having engaged around 200 health systems by the end of FY25, management's priority is deeper adoption within existing accounts, so evidence that ULT and OPH volumes are compounding will be closely watched. Tristel's FY25-FY30 targets of double-digit annual revenue growth, at least 25% adjusted EBITDA margins and a progressive dividend give a clear yardstick. Monetising 3T Pro, expanding VISICLEAN, launched in September 2025, and further growth in rest-of-world markets, where FY25 revenue rose 36%, are additional levers.

Risks investors should watch

Leadership transition is the most immediate uncertainty: a chief executive has left at the end of a strong year and execution now rests on a new appointee. US progress is real but tiny: £262k of first-half revenue is barely 1% of group sales, and the route to market depends on a single partner, Parker Laboratories, and on the pace of hospital protocol change.

The company relies heavily on one product family, with medical device decontamination at 88% of revenue, and on its chlorine dioxide chemistry; regulatory changes in the UK, EU or US could affect demand. Roughly two-thirds of sales are overseas, creating currency exposure. At about 400p the shares trade on roughly 29 times FY25 basic EPS, according to lse.co.uk, so any slowdown from double-digit growth could weigh on sentiment. As an AIM stock valued under £200m, Liquidity can be thin.

Outlook

Tristel enters FY27 with a record cash balance, no debt, clearly stated growth targets and a new chief executive chosen for his US experience. The October results will show whether the £11.5m profit floor is beaten and how the second half fared. Beyond that, the case rests on the US moving from promising to material, on 3T Pro proving that hospitals will pay for software, and on margins holding above 25% as Investment continues. For a company that already ticks the growth, cash and dividend boxes, the debate is less about survival than about how much of that consistency is already reflected in the price.